Search for companies, drugs, and catalysts
Drugs in Pipeline
2
Phase 3 Programs
Upcoming Catalysts
0
Next Catalyst
None scheduled
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
Firmonertinib
Non-Small-Cell Lung Cancer
0 upcoming, 0 past
No catalysts found.
